Investigative Therapy to Treat Underlying Cause of Systemic Mastocytosis is Under FDA Review

Blueprint Medicines Corporation has just announced that they have submitted a supplemental New Drug Application (NDA) to the FDA. This application is for a therapy called AYVAKIT, which was developed…

Continue Reading Investigative Therapy to Treat Underlying Cause of Systemic Mastocytosis is Under FDA Review
Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis
source: pixabay.com

Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis

  In a recent press release, precision therapy company Blueprint Medicines Corporation announced positive results from two clinical trials: EXPLORER and PATHFINDER. The trials examined the safety, efficacy, and tolerability…

Continue Reading Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis
The Latest Advances in Systemic Mastocystosis Molecular Biology Could Change Future Treatment
source: pixabay.com

The Latest Advances in Systemic Mastocystosis Molecular Biology Could Change Future Treatment

By Lauren Thayer from In The Cloud Copy Systemic mastocytosis (SM) is a complicated condition of the blood in which excessive numbers of mast cells (a type of white blood…

Continue Reading The Latest Advances in Systemic Mastocystosis Molecular Biology Could Change Future Treatment
Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released
jarmoluk / Pixabay

Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released

Promising data from the ongoing Phase I clinical trial Explorer has been announced by Blueprint Medicines Corporation. The trial is designed to evaluate the effects of the experimental drug avapritinib…

Continue Reading Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released